ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AEZS Stock Price » AEZS Stock News

Aeterna Zentaris Share News

 Aeterna Zentaris (mm) Stock Price
AEZS Stock Price
 Aeterna Zentaris (mm) Stock Chart
AEZS Stock Chart
 Aeterna Zentaris (mm) Stock News
AEZS Stock News
 Aeterna Zentaris (mm) Company Information
AEZS Company Information
 Aeterna Zentaris (mm) Stock Trades
AEZS Stock Trades

FDA Fast Tracks Keryx Colorectal Cancer Drug, Shares Soar

DOW JONES NEWSWIRES Keryx Biopharmaceuticals Inc. (KERX) said the U.S. Food and Drug Administration has given fast-track designation to perifosine, its drug for treating colorectal cancer. Shares of the biopharmaceutical company jumped 25% to $3.43 in recent trading, while U.S.-traded shares of Keryx's Canadian partner Aeterna Zentaris Inc. (AEZ.T, AEZS) were recently up 23% to 99 cents. Drugs given fast-track designation are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs, Keryx said. They usually qualify for expedited review from the FDA. "We believe that commercialization of perifosine in this indication could potentially commence by mid-2012," said Chief Executive Ron Bentsur. Keryx said it expects to begin Phase III testing of the drug in the second quarter of this year, and it expects to complete the study in the second half of 2011. Keryx in December received fast-track status from the FDA for perifosine for the treatment of multiple myeloma. The treatment is licensed by Keryx from Aeterna for the U.S., Canada and Mexico. -By Nathan Becker, Dow Jones Newswires; 212-416-2855; [email protected];

Stock News for Aeterna Zentaris (AEZS)
03/21/201716:35:04Securities Registration (foreign Private Issuer) (f-3)
03/21/201706:04:52Report of Foreign Issuer (6-k)
03/16/201706:05:17Annual and Transition Report (foreign Private Issuer) (20-f)
03/16/201706:05:16Report of Foreign Issuer (6-k)
03/15/201716:48:00Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial...
03/07/201708:30:00Aeterna Zentaris Announces EMA Pediatric Committee Agreement...
03/06/201708:30:00Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016...
03/02/201717:00:00Aeterna Zentaris Announces Presentation Regarding Macrilen™ a...
02/14/201717:30:00Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate C...
02/13/201707:30:00Aeterna Zentaris Announces Plans to Pursue FDA Registration of...
02/09/201708:30:00Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth...
02/07/201716:15:00Aeterna Zentaris to Present at the 2017 BIO CEO and Investor...
01/30/201717:30:00Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3...
01/09/201714:22:43Amended Statement of Ownership (sc 13g/a)
01/05/201712:49:24Report of Foreign Issuer (6-k)
01/04/201717:15:00Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase...
11/08/201617:29:46Report of Foreign Issuer (6-k)
11/08/201617:21:43Report of Foreign Issuer (6-k)
11/08/201616:45:00Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating...
11/01/201612:07:47Report of Foreign Issuer (6-k)

Aeterna Zentaris and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations